PL417983A1 - Zastosowanie medyczne 5,7-dihydroksy-3-(4-hydroksyfenylo)-4H-1-benzopiran-4-onu w terapii choroby Huntingtona oraz farmaceutycznie akceptowalna postać leku - Google Patents
Zastosowanie medyczne 5,7-dihydroksy-3-(4-hydroksyfenylo)-4H-1-benzopiran-4-onu w terapii choroby Huntingtona oraz farmaceutycznie akceptowalna postać lekuInfo
- Publication number
- PL417983A1 PL417983A1 PL417983A PL41798316A PL417983A1 PL 417983 A1 PL417983 A1 PL 417983A1 PL 417983 A PL417983 A PL 417983A PL 41798316 A PL41798316 A PL 41798316A PL 417983 A1 PL417983 A1 PL 417983A1
- Authority
- PL
- Poland
- Prior art keywords
- benzopyran
- dihydroxy
- hydroxyphenyl
- therapy
- medicine
- Prior art date
Links
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 title abstract 6
- 208000023105 Huntington disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Przedmiotem zgłoszenia jest zastosowanie medyczne 5,7-dihydroksy-3-(4-hydroksyfenylo)-4H-1-benzopiran-4-onu do wytwarzania leku powodującego zmniejszenie wielkości i liczby agregatów białkowych w komórkach, spadek całkowitego poziomu zmutowanej formy białka oraz wzrost przeżywalności komórek. Ponadto, przedmiotem zgłoszenia jest kompozycja farmaceutyczna zawierająca substancję aktywną 5,7-dihydroksy-3-(4-hydroksyfenylo)-4H-1-benzopiran-4-on w połączeniu z co najmniej jednym nośnikiem lub rozcieńczalnikiem farmaceutycznym, do zastosowania w leczeniu choroby Huntingtona.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL417983A PL417983A1 (pl) | 2016-07-15 | 2016-07-15 | Zastosowanie medyczne 5,7-dihydroksy-3-(4-hydroksyfenylo)-4H-1-benzopiran-4-onu w terapii choroby Huntingtona oraz farmaceutycznie akceptowalna postać leku |
EP17001178.7A EP3300730B1 (en) | 2016-07-15 | 2017-07-11 | The medical use of 5,7-dihydroxy-3-(4-hydroxyphenyl)-4h-1-benzopiran-4-one in the therapy of huntington disease and pharmaceutically acceptable form of the drug |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL417983A PL417983A1 (pl) | 2016-07-15 | 2016-07-15 | Zastosowanie medyczne 5,7-dihydroksy-3-(4-hydroksyfenylo)-4H-1-benzopiran-4-onu w terapii choroby Huntingtona oraz farmaceutycznie akceptowalna postać leku |
Publications (1)
Publication Number | Publication Date |
---|---|
PL417983A1 true PL417983A1 (pl) | 2018-01-29 |
Family
ID=61006882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL417983A PL417983A1 (pl) | 2016-07-15 | 2016-07-15 | Zastosowanie medyczne 5,7-dihydroksy-3-(4-hydroksyfenylo)-4H-1-benzopiran-4-onu w terapii choroby Huntingtona oraz farmaceutycznie akceptowalna postać leku |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3300730B1 (pl) |
PL (1) | PL417983A1 (pl) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL440896A1 (pl) | 2022-04-11 | 2023-10-16 | Uniwersytet Gdański | Genisteina do zastosowania w zapobieganiu utraty pamięci i zdolności poznawczych ludzi zdrowych w wyniku stopniowych występujących fizjologicznie u osób zdrowych procesów starzenia się mózgu z wiekiem jako czynnik zapobiegający i zmniejszający odkładanie się szkodliwych nierozpuszczalnych agregatów i złogów białek w mózgu, zwłaszcza beta-amyloidu |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009516751A (ja) * | 2005-11-21 | 2009-04-23 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティー・オブ・アラバマ・フォー・アンド・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アラバマ | 神経保護のための小分子化合物を使用する方法 |
-
2016
- 2016-07-15 PL PL417983A patent/PL417983A1/pl unknown
-
2017
- 2017-07-11 EP EP17001178.7A patent/EP3300730B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3300730A1 (en) | 2018-04-04 |
EP3300730B1 (en) | 2024-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020012041A (es) | Formulacion farmaceutica. | |
NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
MX2017011280A (es) | Terapia neuro-afectiva regional topica con cannabinoides. | |
TR201901312T4 (tr) | Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri. | |
CO2018006358A2 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
BR112015022433A2 (pt) | dispositivos de liberação de droga com componente permeável à droga e métodos | |
MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
BR112018003870A2 (pt) | construções cirúrgicas tubulares incluindo material auxiliar | |
AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
SG10201906400SA (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
MX2018010032A (es) | Formulaciones de antagonista de il-6 y sus usos. | |
MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
Lopez-Garcia et al. | Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections | |
BR112018010066A2 (pt) | agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo | |
PL417983A1 (pl) | Zastosowanie medyczne 5,7-dihydroksy-3-(4-hydroksyfenylo)-4H-1-benzopiran-4-onu w terapii choroby Huntingtona oraz farmaceutycznie akceptowalna postać leku | |
BR112018016287A2 (pt) | sistema de perfusão, método para administrar diretamente a um paciente em necessidade do mesmo uma dose de um fármaco antineoplásico e recipiente de perfusão | |
Berk et al. | Randomized phase 2 trial of best supportive care: Manuka honey liquid and Manuka honey lozenges for prevention of radiation esophagitis during chemotherapy and radiation therapy for lung cancer | |
MX2021001349A (es) | Un nuevo tratamiento medico para la inflamacion patologica. | |
Long et al. | QHMEM, a Quinazolinone Compound, Inhibits Proliferation and Induces Apoptosis in Human Colon Cancer HCT116 Cells | |
RU2015154876A (ru) | Способ хирургического лечения диабетического макулярного отека с наличием витреомакулярной тракции | |
Golpayegani et al. | The Comparison of Desfonak with Desferal in Patients with Beta Thalassemia Major: A Randomized Crossover Clinical Trial |